89Bio Inc

ETNBStocksPharmaceuticals MajorUnited StatesNasdaqUSD

Price

$14.50

Today

+0.0%

YTD

-2.2%

About

89bio, Inc. is a clinical-stage biopharmaceutical company operating in the field of biotechnology. Primarily focused in the United States, the company is engaged in developing innovative therapies to treat liver and cardio-metabolic diseases. 89bio operates in the healthcare industry. Through its bioscience technology, 89bio, Inc. develops a portfolio of products, including pegozafermin, which is engineered to treat diseases such as nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Keep up-to-date on the latest share price changes by adding ETNB stock to your eToro watchlist.

Price chart

Closing price history for ETNB (1D candles).

Open positions

Current open positions for this instrument from your live portfolio.

Open positions

Unrealized return

+0.0%

No open positions exist for this instrument at the moment.

Financial insights

Valuation

P/E (TTM)-4.12

P/S (TTM)0.00

P/B (TTM)4.22

Market cap$2.20B

Cap tierMid-cap

Industry avg P/E-7.28

Profitability

Gross marginUnknown

EBIT margin0.00%

Net marginUnknown

ROE-86.86%

ROA-75.94%

Earnings & Revenue

Revenue (TTM)$0.00

Revenue growth (1Y)Unknown

EPS (TTM)-$3.61

Free cash flow$-439.19M

Total debt$37.62M

Dividends & Risk

Dividend rate$0.00

Dividend yield0.00%

Beta (5Y)1.25

Employees93

Next earnings6 Nov '25

Trade history

Closed trades

Realized return

+0.0%

No stored closed trades exist for this instrument yet.